Crizotinib is a anti cancer medication used for the treatment of non small cell lung carcinoma (NSCLC) or relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL). It acts as an ALK (anaplastic lymphoma kinase) and ROS1 (c ros oncogene 1) inhibitor.
It is also indicated for the treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK) positive myofibroblastic tumors (IMT).
Crizotinib is also being tested in clinical trials of advanced disseminated neuroblastoma.
